Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Probi, Audiocast with teleconference, Q3'24

By Inderes10/22/2024, 8:00 AM
Probi

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Anita Johansen
00:01 - 02:33

Good morning. Welcome and thank you for dialing in to the Probi presentation of our Q3 results for 2024. With me, I have Per Lindblad, the CFO of Probi, and my name is Anita Johansen. I'm the CEO of Probi. Please take a few moments to familiarize yourself with this safe harbor statement. And this is the agenda of our presentation today. So here are the highlights of Q3, which, in contrast to the second quarter, was a slow quarter. On the right side, you can see that the net sales totaled 144 million Swedish kronor, and the EBITDA margin for Q3 was 20%. Per Lindblad will talk a little bit more about these numbers in the coming slides. With regards to our business operations, this quarter was characterized by the following highlights. Our sales activities continued with strong customer engagement through a workshop we held in APAC. We had trade shows, exhibitions, and customer meetings. Also, we have completed a rebranding of our business-to-consumer product line in the Nordics, and we are now finalizing a new corporate identity to also enhance our market presence for the B2B. Our optimization efforts in our US operations are now yielding tangible results, and we can already see the improvements. Our new consumer product line, which contains the strain HEAL9, was launched in the Nordics just after the quarter closed. And from a research perspective, we have several interesting and exciting new results. First of all, we have a new study in mice that suggests that our strain HEAL9 may serve as a potential therapeutic option for mitigating mild cognitive impairment and potentially even Alzheimer's disease. Also, we have recently announced a research collaboration and an intention to collaborate on a new study with Global Brain Trust and the Fingers Brain Health Institute, aimed at reducing dementia risk. Lastly, we also successfully completed a SMETA 4-Pillar audit in our US operations. This further cements our commitment to sustainable and ethical business practices. And now I'll hand over to Per Lindblad for the Financial Review.

Per Lindblad
02:35 - 10:25

Thank you, Anita. Yeah. The sales in Q3 were 144 million. SEK. But I will also highlight that our business is 75% in the US. Hence, the organic growth is the most relevant metric to gauge the overall sales performance in Q3. We saw organic growth decline by 5% compared to the same quarter in 2023. But also, what you see here is that the reported growth is down 8% compared to last year. So the relevant context for this result is that the overall US probiotic market on a volume basis has contracted since the peak during the pandemic. This is according to the leading market research source, Euromonitor. Beyond this, we also saw various timing impacts in Q3. For the other markets. In EMEA, the overall performance was flat compared to last year. That statement actually covers it. B2B has overall very good traction, but B2C was impacted by timing as we are positioning to leverage the new branding in Q4. The growth in the APAC region is negatively impacted by the general economic slowdown in China, and I will cover this a little more in the following slides. For EBITDA, the result is 20% in Q3. This is an improvement of the EBITDA margin by two percentage points against Q3 last year, and we find that quite exciting because, as Anita said, we have seen improvements in our production KPIs. In Q3, we actually see these improvements beginning to flow into the P&L, improving both the gross profit and the EBITDA. Now, examining the regional segments on a year-to-date basis, the Americas, in constant currency, are down 1% compared to last year. I mentioned earlier the relevant context with the contracting market, but we will really focus now. And that's what our sales team is doing: building the pipeline. That's what it's all about. This involves various activities, including our insight team promoting Probi at the major US trade show, SupplySide West in Las Vegas, next week. Here, they will showcase both the new branding and launch the Metabolic health concept specifically for the US. The gross profit margin is down on a year-to-date basis, but very importantly, it was actually up in Q3. So in H1, we saw that gross profit was impacted by the added resources, for example, in operations to facilitate the improvements in production. And the result is exactly what we see now. And we are, as I mentioned, quite excited by this. EMEA sales are up significantly compared to 2023, actually 29% on a year-to-date basis. Most of those improvements are related to low comparisons in 2023. We earlier mentioned that we had to reduce overstocking in a few big accounts in 2023, and now the sales are normalizing. This is a favorable impact. And also in 2023, we experienced a very significant impact from the insourcing of our B2C business. The sales in Q3 are actually at the same level as last year. And as mentioned, this is good news as B2C is reduced to facilitate the new branding in Q4. The high growth in EMEA helps Probi overall to improve profitability. This is because EMEA, as you can tell from the slides, has above-average profitability. So, this is driving the overall profitability for Probi, yet it should be noted that the margin is below last year. Specifically for EMEA, though, there are very specific reasons related to customer and product mix. Now, regarding APAC, sales in Q3 were below expectations and came after similar soft sales in previous quarters. Sales in the APAC region were impacted by a general economic slowdown, specifically in China, and tougher market conditions, which have caused delays in product launches and reduced commercial traction. Probi continued its market activity at a high pace in the region to maintain momentum and foster long-term relationships, but importantly, Probi has maintained its market position and not lost any customers. On the gross margin in Q3, it was up compared to last year. Yet, on a year-to-date basis, it was impacted by an adverse customer mix. The net income for Q3, compared to the same quarter last year, shows that sales volume is down as reported earlier. Organically 5%, which is here quantified as an adverse volume impact of 3.5 million. The gross profit is favorably impacted due to the improved margins in Q3 of 2.4. OpEx has improved, as mentioned in the report, for example through higher capitalization of R&D costs, timing of marketing costs for B2C, and a few other factors. Overall, the impact is 0.5 for the quarter. The financial result is also driven by FX gains and losses for bank accounts and foreign currency. And overall, this means that net income is 4.0 million for the quarter, which compares to 6.4 million last year and hence is 2.4 million down in the quarter. Solid cash generation on a year-to-date basis. Operating cash flow of 85 million for the nine-month period. We continue to invest in Q3, and now, it's at a level of 38 million. Year to date, this CapEx covers both plant and machinery. In our production facilities, we cover not only the machinery and equipment but also the R&D project costs to support the sales pipeline. Financing, by and large, is the least costly aspect related to our main production sites in the US, and as this statement covers year to date, we also include the Q2 dividend payout of 15 million. All in all, resulting in a cash end of period of 349 million. And now I'd like to hand over to Anita.

Anita Johansen
10:26 - 10:27

Thank you. Per Lindblad.

Unknown 1
10:27 - 10:28

Next slide, please.

Anita Johansen
10:30 - 11:30

So this past year has been a pivotal period of internal transformation aimed at unlocking the full potential of Probi. Let me emphasize three key focus areas where we are seeing progress. One, we are seeing tangible improvements in our operations. And two, we continue to build new insights on our product portfolio, and we continue to bring new state-of-the-art advanced biotech solutions to market. And three, we have been investing in our marketing and sales resources and strengthening and reinventing our market presence. And we will continue to focus hard on our efforts to accelerate our growth. So we are proud of the progress so far, although we do recognize it's an ongoing journey and further work remains. We are committed to maintaining a steady course with a focus on long-term growth and sustainable success. So this concludes our presentation of the Q3 Interim Report 2024. And now there's time for questions.

Operator
11:33 - 11:54

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Philip Ekengren from ABG. Ask. Please go ahead.

Philip Ekengren
11:56 - 12:27

Thank you. Operator. Good morning, Anderson. Pat. I have a few questions, and I plan to take them one by one. But first, if we can get some color on the different regions. So, media was strong in Q2 and flat. Now I would like some clarification on the commercial efforts you're making in the Nordic region, mainly related to the B2C business. Did these initiatives begin in Q3 and will they continue into Q4, or should we expect them to start yielding results on sales already in Q4?

Anita Johansen
12:29 - 13:35

I can start, and perhaps Pierre can follow up. So first of all, when you visit Swedish pharmacies now, you will see that our products are getting a new artwork. So a new design has been implemented, and we are rolling this out starting early October. So you will see that out in the pharmacies now because of the rollout of new artwork, we have consequently seen a decline in the sales of the old artwork. Obviously, we want to have this changeover as quickly as possible. So we have had limited sales to the pharmacies in the last few months, and we are now expecting to fill up the shelves in the coming months, specifically in the fourth quarter. Now when we have the new artwork in place and also our new introduction of the Probi scent. So, with the new launch, we will intensify the campaigns with our customers, the pharmacies in the Nordic region. So the campaigns will increase, and hopefully, we will see. We expect to see much more activity. I don't know if you want to add anything here.

Per Lindblad
13:36 - 13:38

No, I think that covers it very well.

Philip Ekengren
13:41 - 13:56

Perfect. Very clear. Thank you. Um, and if we look at APAC, China is comparing negatively here. Would you like to elaborate what's happening in the market and if you're making any mitigating activities to protect sales going forward?

Unknown 2
13:58 - 13:59

Yes.

Anita Johansen
13:59 - 14:58

I mean, what we are seeing in the APAC market is specifically related to China. And everybody knows that when you look into China right now, they are facing some macroeconomic challenges overall in the Chinese market. And consumers are carefully considering where to spend their money. So, that of course affects our customers in China. They are putting consumer products on the market with our ingredients. Our customers are seeing a decline in sales, and hence they are reducing the need for ingredients for a while. They are not placing orders as often as we would have expected, so to speak. They have more inventory than expected. So that's basically what we see from our customers; they are experiencing slower sales. We are not seeing any significant changes. We're not losing any customers; they are just experiencing a slower market.

Unknown 1
14:59 - 15:00

Yes.

Per Lindblad
15:00 - 15:28

And adding to this, these are the short-term impacts. But clearly, the APAC market is still very attractive. It's huge. So we have these bumps on the road. But we continue to invest in the market. There's a high focus from the team. We have development initiatives specifically targeting this market. So, we see these bumps. But we have a steady course ahead.

Anita Johansen
15:28 - 16:05

And maybe I can add to that. I mean, I've been in APAC several times this year. Last time, I was in Bangkok where we had a full day with more than 20 customers from 20 different companies that we are engaging with; they hail from China as well as other markets in APAC. And there's a very high interest in producing products. Both of the existing products that we've had for a long time, but also our new innovations. There's high interest, but also, of course, it will take time for our customers to implement in their innovation portfolios. We know that, but the interest is definitely there. Also in China.

Philip Ekengren
16:08 - 16:22

Got it. Thanks. Um, and in the US, you're highlighting that the demand is lower and volumes are lower. Can you say anything about what you expect going forward in the US specifically?

Per Lindblad
16:25 - 17:31

It's very, very difficult to predict the market. But one source, which we are putting some effort and credit into, is that of Euromonitor, the leading market research company? They are projecting an outlook for the North American market of 2 to 3% value growth over the coming years. So. So we think that the slowdown we are seeing is coming after a record year under the pandemic. So, we are not concerned about the overall market outlook in the Americas. Um, but a little bit like APAC. And we see various parts of our business experiencing ups and downs, especially by quarters, but also by years. So again, it's a steady course. And, we continue to invest in the North American market. It's huge for us. And the market is huge. So, steady. Course.

Philip Ekengren
17:35 - 17:51

Got it. And if we look at the cost control, you have maintained very good cost control, protecting the margins throughout this quarter. Would you like to give some more color on that, and maybe comment on what we can expect in the coming quarters as well?

Unknown 1
17:56 - 17:56

Yes, we will.

Per Lindblad
17:56 - 18:42

So first of all, let me say we will not be giving forward-looking statements today. Um, but as we read in our report and we also use language to say that we are quite excited by the improvements and the outcomes. As we say, tangible improvements in our production KPIs are obviously excellent news. And, um, I think we can say that there's obviously no reason to think that it should go backwards. We have invested a lot of resources, as we said earlier, to achieve these results. So we are confident that these results are here to stay. And, yeah, we are excited by the results.

Unknown 2
18:42 - 18:45

And yeah.

Anita Johansen
18:45 - 19:14

Maybe I can add to that because, if I understand your question correctly, I mean, yes, we are implementing very prudent cost controls this quarter. We know we have some challenges in our sales, especially from APAC. Hence, we've also been limiting our expenses, so to speak, and only traveling when it's absolutely needed. When we're out to see customers, of course, we will travel, but we're really taking this control internally to make sure we're not spending money unwisely.

Philip Ekengren
19:18 - 19:21

Sounds very good. Thank you. And then, the final question from me.

Unknown 1
19:22 - 19:23

Okay.

Unknown 3
19:26 - 19:27

Sorry.

Philip Ekengren
19:27 - 19:28

Please, please go ahead.

Per Lindblad
19:29 - 19:43

No, I wanted to build on Anita's comment that cost control is not the main driving factor in the numbers. It is what we said. It's.

Unknown 1
19:43 - 19:44

Production.

Per Lindblad
19:44 - 20:04

It is a matter of timing in the OPEX overall. And yes, we are a small company. We manage our money well. We spend only what is needed. So, and that obviously helps. But it's not driving the EBITDA in the quarter. I think I wanted to make that clear.

Anita Johansen
20:04 - 20:06

Thank you. Philip, do you have more questions?

Philip Ekengren
20:09 - 20:19

Maybe just one final question. You previously said that you wanted to stay in line with the 2023 numbers. Is that still the goal for this year?

Unknown 2
20:20 - 20:20

Yes.

Anita Johansen
20:21 - 20:32

We have no other information than what we have previously declared in the Q2 report, which is expected to be in line with last year's result. Yes.

Philip Ekengren
20:35 - 20:37

Perfect. Thanks so much. All for me.

Unknown 2
20:38 - 20:39

Thank you.

Operator
20:43 - 21:03

As a reminder, if you wish to ask a question, please dial the pound key five on your telephone keypad. The next question comes from Rolf Karp from HSBC Arena. Please go ahead.

Rolf Karp
21:06 - 21:18

Thank you. Just two questions. Could you please give us some insight into the competition? What are the competitors doing currently, and what do you see going forward?

Anita Johansen
21:21 - 22:58

Thank you for that question. Um, on competition, I mean, I can mostly speak about Probi, obviously, but of course, we see consolidation in the industry, right? So some of our competitors have created some major, major mergers and acquisitions ecosystems. Yeah. Mergers and acquisitions basically create ecosystems. So. So they are probably busy with their internally focused alignment of their organization, I would guess. Obviously, I do not know. That's one aspect to consider. Other than that, I don't really know. I mean, I think what Probi really can benefit from is that we have excellent science, and also we have science-backed product launches in new areas where our competitors are not really settled at this point in time. So we have been active since last year and also this year now in the Nordics with our Probi, the probiotic that is beneficial for mental health, which is something quite unique in the industry. And as Pierre slightly alluded to in one of his comments in the slides, next week we are going to SupplySide West, which is the biggest event in the U.S. In North America, we are actually going to launch not only our new updated branding but also our visual identity, and we're also going to launch a new product next week. So follow us. Um, so, and that's also in an area that is very new in the probiotics industry, which is metabolic health. So I mean, competition is obviously busy, but we don't feel threatened at this point with our product launches and our business.

Rolf Karp
23:02 - 23:05

Okay. Thank you for your answer. That concludes my question.

Anita Johansen
23:06 - 23:07

Thank you very much, Ralph.

Operator
23:14 - 23:20

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Anita Johansen
23:21 - 23:40

Thank you. So now, please note this financial calendar, which has updated dates for the coming year, where we would, of course, invite you to join us and listen to how it's going for Probi. And then I just have to say thank you for listening and have a wonderful rest of your day. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…